| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/11/2001 | DE19932315A1 Benzoylpyridazine Benzoylpyridazine |
| 01/11/2001 | DE19916108C1 Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung With sugar residues substituted 1,4-benzothiazepine-1,1-dioxide derivatives, processes for their preparation and their use |
| 01/11/2001 | CA2643231A1 Norepinephrine reuptake inhibitors and methods of using the same |
| 01/11/2001 | CA2380866A1 Selective npy (y5) antagonists |
| 01/11/2001 | CA2378116A1 Human immune response molecules |
| 01/11/2001 | CA2377784A1 Novel genes and their use in the modulation of obesity, diabetes and energy imbalance |
| 01/11/2001 | CA2377684A1 Screening method |
| 01/11/2001 | CA2376673A1 Substituted purine derivatives as inhibitors of cell adhesion |
| 01/11/2001 | CA2376657A1 Indole derivatives and their use for the treatment of osteoporosis amongst other applications |
| 01/11/2001 | CA2376513A1 An interleukin-1 receptor antagonist and uses thereof |
| 01/11/2001 | CA2375157A1 A method for the improvement of transport across adaptable semi-permeable barriers |
| 01/11/2001 | CA2374358A1 Methods and compositions for regulating gut motility and food intake |
| 01/11/2001 | CA2373945A1 Remedies for drug-resistant hypercalcemia |
| 01/11/2001 | CA2373885A1 Therapeutic agent for diseases caused by pth or pthrp |
| 01/11/2001 | CA2373883A1 Method of reducing neuronal injury or apoptosis |
| 01/10/2001 | EP1066377A1 Methods for prevention and treatment of cancer |
| 01/10/2001 | EP1066316A1 Cinnamic acid derivatives having cell adhesion modulating activity |
| 01/10/2001 | EP1066288A2 Novel compounds |
| 01/10/2001 | EP1066283A2 Substituted indolealkanoic acids |
| 01/10/2001 | EP1066279A1 Imidazolone anorectic agents: ii. phenyl derivatives |
| 01/10/2001 | EP1066278A1 Imidazolone anorectic agents: iii. heteroaryl derivatives |
| 01/10/2001 | EP1066262A1 Imidazolone anorectic agents: i. acyclic derivatives |
| 01/10/2001 | EP1065945A1 Method for producing a fat mixture |
| 01/10/2001 | CN1279691A Antibodise against phosphorylated VASP (vasodilator-stimulated phosphoprotein), hybridoma cells for their preparation, and their use |
| 01/10/2001 | CN1279689A Vitamin D receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof |
| 01/10/2001 | CN1279682A bicyclic kinase inhibitors |
| 01/10/2001 | CN1279666A NPY antagonists |
| 01/10/2001 | CN1279617A Combination of an aldose reductase inhibitor and a glycogen phosphorglase inhibitor |
| 01/10/2001 | CN1279613A Use of sulfated oligosaccharides in lowering blood triglyceride levels |
| 01/10/2001 | CN1279606A Use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function |
| 01/10/2001 | CN1279605A Inihibition of lipoprotein oxidation |
| 01/10/2001 | CN1279105A Hypoglyemic liquid medicine |
| 01/10/2001 | CN1279080A Gingko tea and preparing process thereof |
| 01/10/2001 | CN1279073A Antisenility Chinese medicine |
| 01/10/2001 | CN1279036A Method and composition for extending sevice life of intestinal canal |
| 01/10/2001 | CN1060373C Drug for curing diabetes and its preparing method |
| 01/10/2001 | CN1060352C Blood-fat reducing medicine and preparing process thereof |
| 01/09/2001 | US6172256 Chiral-β-amino acid compounds and derivatives thereof |
| 01/09/2001 | US6172250 Hydrolysis of an organosilicon compounds |
| 01/09/2001 | US6172111 Salt formation; antiobesity and strengthening agents |
| 01/09/2001 | US6172108 Hydrazide compounds |
| 01/09/2001 | US6172103 Treating bone disorders, osteoporosis, and arthritis |
| 01/09/2001 | US6172097 Treating psychological, eating, sexual, and nervous system disorders; anxiolytic, adrenergic blocking, and antidepressant agents; serotonin reuptake inhibitors |
| 01/09/2001 | US6172091 Metabolic calcium imbalance and osteoporosis |
| 01/09/2001 | US6172090 Side effect reduction by administering an insulin sensitivity enhancer such as pioglitazone hydrochloride with a biguanide such as metformin |
| 01/09/2001 | US6172089 Pharmaceutical composition |
| 01/09/2001 | US6172071 Anticholesterol agent |
| 01/09/2001 | US6172067 Analgesics, antiinflammatory agents |
| 01/09/2001 | US6171815 Human sulfonylurea receptor |
| 01/09/2001 | US6171590 Treatment and prevention of inflammatory responses. |
| 01/09/2001 | US6171588 Anti-αvβ3 integrin antibody antagonists |
| 01/04/2001 | WO2001001130A1 METHODS AND COMPOSITIONS RELATING TO PANCREATIC ISLET AND β-CELL DYSFUNCTION |
| 01/04/2001 | WO2001000881A1 Antisense modulation of pi3k p85 expression |
| 01/04/2001 | WO2001000830A1 Sgip peptides |
| 01/04/2001 | WO2001000824A2 HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS |
| 01/04/2001 | WO2001000812A2 22012, a novel human carboxypeptidase |
| 01/04/2001 | WO2001000811A2 17867, a novel human aminopeptidase |
| 01/04/2001 | WO2001000808A1 Antisense modulation of ship-2 expression |
| 01/04/2001 | WO2001000676A1 Somatostatin agonists |
| 01/04/2001 | WO2001000654A2 Purification and stabilization of peptide and proteins in pharmaceutical agents |
| 01/04/2001 | WO2001000653A1 Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease |
| 01/04/2001 | WO2001000622A1 Prodrugs of carbamate inhibitors of impdh |
| 01/04/2001 | WO2001000618A1 Benzamide derivatives |
| 01/04/2001 | WO2001000616A1 Cholesterol biosynthesis inhibitors containing as the active ingredient aromatic compounds bearing cyclic amino groups |
| 01/04/2001 | WO2001000613A1 Benzimidazole compounds and drugs containing the same |
| 01/04/2001 | WO2001000606A1 Process for selective lactonization |
| 01/04/2001 | WO2001000603A1 Thiazole and oxazole derivatives and their pharmaceutical use |
| 01/04/2001 | WO2001000588A1 Benzimidazole compounds and drugs containing the same |
| 01/04/2001 | WO2001000587A1 Azolylbenzamides and analogues and their use for treating osteoporosis |
| 01/04/2001 | WO2001000585A1 Pyrazolidinol compounds |
| 01/04/2001 | WO2001000579A1 COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY |
| 01/04/2001 | WO2001000570A1 Intermediates for the synthesis of benzimidazole compounds and process for the preparation thereof |
| 01/04/2001 | WO2001000566A2 Substituted phenoxyacetic acids |
| 01/04/2001 | WO2001000223A2 Multiple agent diabetes therapy |
| 01/04/2001 | WO2001000220A2 Lipoprotein lipase (lpl) variant therapeutics |
| 01/04/2001 | WO2001000210A1 Reverse-turn mimetics and methods relating thereto |
| 01/04/2001 | WO2001000206A1 Vla-4 inhibitor compounds |
| 01/04/2001 | WO2001000205A1 Pharmaceutical composition containing sibutramine and orlistat |
| 01/04/2001 | WO2001000187A2 Pharmaceutical composition containing sibutramine and a lipase inhibitor |
| 01/04/2001 | WO2001000186A2 New use of 1,2,4-triazolo'1,5-a! pyrimidines |
| 01/04/2001 | WO2001000185A2 1,4-denzothiazepines to treat obesity related disorders |
| 01/04/2001 | WO2001000183A2 COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS |
| 01/04/2001 | WO2001000166A1 Cosmetic compositions containing pantothenic acid |
| 01/04/2001 | WO2001000047A1 Prophylactic dietary supplement based on milk |
| 01/04/2001 | WO2001000046A1 Use of nanoscale sterols and sterol esters |
| 01/04/2001 | WO2000057921A3 Peroral gene therapy of diabetes and obesity |
| 01/04/2001 | CA2385798A1 Substituted phenoxyacetic acids |
| 01/04/2001 | CA2378227A1 Antisense modulation of pi3k p85 expression |
| 01/04/2001 | CA2377752A1 Methods and compositions relating to pancreatic islet and .beta.-cell dysfunction |
| 01/04/2001 | CA2377721A1 Sgip peptides |
| 01/04/2001 | CA2377492A1 Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease |
| 01/04/2001 | CA2377437A1 Antisense modulation of ship-2 expression |
| 01/04/2001 | CA2377265A1 Somatostatin agonists |
| 01/04/2001 | CA2377204A1 Purification and stabilization of peptide and protein pharmaceutical agents |
| 01/04/2001 | CA2377200A1 Pyrazolidinol compounds |
| 01/04/2001 | CA2376886A1 Therapeutic agents |
| 01/04/2001 | CA2376881A1 Combination of mtp inhibitors and hmg-coa reductase inhibitors and the use thereof in medicaments |
| 01/04/2001 | CA2376840A1 Cosmetic compositions containing pantothenic acid |
| 01/04/2001 | CA2376818A1 Use of nanoscale sterols and sterol esters |
| 01/04/2001 | CA2376213A1 Therapeutic agents |